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Abstract
Background: The identification of variants in the nicotinic acetylcholine receptor (nAChR) subunit genes associated
with smoking phenotypes are increasingly important for prevention and treatment of nicotine dependence. In the
context of personalized medicine, the aims of this study were to evaluate whether cholinergic receptor nicotinic
alpha 2 (CHRNA2), cholinergic receptor nicotinic alpha 3 (CHRNA3), cholinergic receptor nicotinic alpha 5 (CHRNA5)
and cholinergic receptor nicotinic beta 3 (CHRNB3) polymorphisms were associated with nicotine dependence
severity, and to investigate possible pharmacogenetics markers of smoking cessation treatment.
Methods: This study cohort enrolled 1049 smoking patients who received pharmacological treatment (varenicline,
varenicline plus bupropion, bupropion plus/or nicotine replacement therapy). Smoking cessation success was
considered for patients who completed 6 months of continuous abstinence. Fagerström test for nicotine
dependence (FTND) and Issa situational smoking scores (Issa score) were analyzed for nicotine dependence.
CHRNA2 (rs2472553), CHRNA3 (rs1051730), CHRNA5 (rs16969968 and rs2036527) and CHRNB3 (rs6474413)
polymorphisms were genotyped by high resolution melting analysis.
Results: Females with GA and AA genotypes for CHRNA5 rs16969968 and rs2036527 polymorphisms had higher
success rate in smoking cessation treatment: 44.0% and 56.3% (rs16969968), 41.5% and 56.5% (rs2036527),
respectively, compared with carriers of the GG genotypes: 35.7% (rs16969968), 34.8% (rs2036527), (P = 0.03, n = 389;
P = 0.01, n = 391). The GA or AA genotypes for the rs16969968 and rs2036527 were associated with higher odds
ratio for success in women (OR = 1.63; 95% CI = 1.04 to 2.54; P = 0.03 and OR = 1.59, 95% CI = 1.02 to 2.48; P = 0.04;
respectively). We did not find association of these polymorphisms with nicotine dependence related scores.
Polymorphisms in the CHRNA2, CHRNA3 and CHRNB3 genes were not associated with the phenotypes studied.
Conclusion: CHRNA5 rs16969968 and rs2036527 were associated with higher success rate in the smoking cessation
treatment in women. These findings might contribute to advances in personalized medicine.
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Background
Smoking is a serious public health problem, contributing
significantly to the risk of death from cancers, cardiovas-
cular diseases, lung disorders and stroke. Public health
agencies aim to reduce tobacco use; however, relapse is
common during smoking treatment programs. Accord-
ing to the World Health Organization, if current trends
continue, the annual number of deaths from diseases re-
lated to smoking could double from five million in 2000
to 10 million in 2020 [1, 2].
Studies have shown that although smoke toxicity is re-
lated to many components of the cigarette, nicotine is
responsible for the development of dependence [3, 4].
Smokers in Brazil who want to quit have the following
first-line pharmacological treatments: nicotine replace-
ment therapy (NRT), bupropion (an inhibitor of the re-
uptake of norepinephrine, dopamine and nicotinic
antagonist) and, varenicline (a partial agonist of nicotinic
acetylcholine receptor - nAChR - α4β2) [5–7].
Cigarette smoking is classified as a complex behavior
comprising multiple stages such as initiation, experimen-
tation, regular use, addiction, cessation and relapse [8,
9]. To better understand the role played by genes in
those stages, twin studies, and allelic association studies
of candidate genes and large genome wide-association
studies are increasingly required [8–10].
In the last ten years, several studies have identified
loci, mainly in chromosome 8 and 15, which are highly
involved in the pathogenesis of nicotine dependence
(ND) process. These regions of the genome include
genes encoding various subunits of the nAChR. These
receptors are expressed in the brain and are thought to
be responsible for mediating the addictive effects of
nicotine [1, 8, 10–14]. Therefore, studies have shown the
association of polymorphisms in genes encoding the
subunits of nicotinic receptors (CHRNA2, CHRNA3,
CHRNA5, CHRNB3) with the number of cigarettes per
day, ND and risk for developing lung cancer [1, 8, 13,
15, 16].
In the context of personalized medicine, the aims of
the present study were to evaluate whether CHRNA2,
CHRNA3, CHRNA5 and, CHRNB3 polymorphisms were
associated with level of dependency and, response to
smoking cessation therapies in patients from a smoking
cessation assistance program.
Methods
Study population
The study sample included 1049 smoking patients from
PAF (Programa de Assistência ao Fumante /Smoker As-
sistance Program), Heart Institute (InCor), University of
Sao Paulo Medical School, Sao Paulo, Brazil, between
January, 2007 and November, 2014. The study protocol
was approved by the Institutional Ethics Committee
(Comissão de Ética para Análises de Projetos de Pes-
quisa - CAPPesq − 4024/14/004), and written informed
consent was obtained from all participants prior to en-
tering the study. Data from patients who had outcome
in smoking treatment were obtained from the PAF
database.
The PAF protocol consists of an initial medical visit
plus an average of 4 follow-up medical visits for
12 weeks. The follow-up was made by phone in patients
who did not continue to come on scheduled medical
visits. Clinical data and end-expiratory exhaled carbon
monoxide (CO) were collected in all visits. Data about
demographic, socio-economic, clinical data and previ-
ously diagnosed diseases were acquired at the consult.
During clinical anamnesis patients were questioned
whether they were undergoing treatment or had a diag-
nosis of depression and/or anxiety. Patients received be-
havioral counseling and drug treatment from physicians
specialized in smoking cessation. Bupropion plus/or
NRT was prescribed for patients who smoked less than
1 cigarette pack per day. Varenicline was prescribed for
patients who smoked 1 or more cigarette pack(s) per
day, or who failed in previous attempts with bupropion
plus/or NRT. The decision to start co-administration of
bupropion and varenicline was made if the patient was
unable to quit smoking after 2 or 3 months of starting
varenicline use, or if the patient stopped smoking, but
presented moderate or intense discomfort abstinence
symptoms. Continuous abstinence (CA) was investigated
after 6 months of starting pharmacotherapy. Smoking
status (outcome) was divided into: success group (pa-
tients who completed 6 months of CA confirmed by
end-expiratory exhaled carbon monoxide < 4 ppm), re-
lapse group (patients who did not complete 6 months of
CA), and resistant group (patients who never achieved
CA after starting drug treatment) [17, 18].
FTND and Issa scores
The Fagerström Test for Nicotine Dependence (FTND)
and the Issa Situational Smoking Score (Issa score) were
used to assess smoking behavior. The FTND is com-
prised of six questions with different weights for each
question, generating a score ranging from 0 to 10 points
and individuals are grouped into five categories: 1–2
points = very low dependence; 3–4 points = low depend-
ence; 5 points = medium dependence; 6–7 points = high
dependence; and 8–10 points = very high dependence
[19]. The Issa score is comprised of four questions, one
point for each affirmative answer, generating a scores
ranging from 0 to 4 points. Individuals are grouped into
categories: 1 point = low dependence; 2–3 points =medium
dependence; 4 points = high dependence [20].
The FTND is a revised version of the Fagerström Tol-
erance Questionnaire (FTQ) and it is based in the
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cigarette consumption, while the Issa score is based on
the psychoactive effects of nicotine on cognitive pro-
cesses, attention, concentration, mood, well-being and
pleasure [20]. The Issa score is used at the PAF to re-
classify nicotine dependent patients who achieved a
FTND score below 5 but have otherwise considerable
ND level in relation to the psychoactive effects of nico-
tine. As consequences of the psychoactive action of
nicotine, smokers can have behaviors that may indicate
the intensity of addiction [20].
Genotyping
The criteria for selection of these polymorphisms was
the number of significant replications in genetic associ-
ation studies.
Genomic deoxyribonucleic acid (DNA) from subjects
was extracted from peripheral blood following a stand-
ard salting-out procedure. Genotyping for the CHRNA2
rs2472553 (c.674C > T), CHRNA3 rs1051730 (c.645C >
T), CHRNA5 rs16969968 (c.1192G > A), CHRNA5
rs2036527 (g.78559273G > A) and CHRNB3 rs6474413
(g.42695921G > A) were performed by polymerase chain
reaction (PCR) followed by high resolution melting
(HRM) analysis according with previous studies [21, 22].
Amplification of the fragment for the CHRNA2
rs2472553, CHRNA3 rs1051730, CHRNA5 rs16969968,
CHRNA5 rs2036527 and CHRNB3 rs6474413 were per-
formed using the primers shown in Additional file 1:
Table S1. As an example, Additional fil 2: Figure S1
shows normalized fluorescence by temperature graphs
for the CHRNA5 rs16969968 polymorphism. Nine per-
cent of the samples were randomly selected and reana-
lyzed as quality controls and gave identical results.
Statistical analysis
Continuous variables are presented as mean and stand-
ard deviation and categorical variables as frequencies.
Chi-square test was performed for the comparative ana-
lysis of treatment outcome in the overall group of pa-
tients and groups of women and men according to the
polymorphisms in CHRNA2, CHRNA3, CHRNA5 and
CHRNB3 genes. The analysis of the Hardy-Weinberg
equilibrium (HWE) was also performed using the chi-
square test. The Student’s t-test was used to compare
values of the FTND score according to polymorphisms
and also, to compare general and clinical characteristics
between men and women. Linear regression models
were conducted to evaluate the influence of polymor-
phisms in FTND in the presence of covariates: age, gen-
der (male), race/self-declared color (white) and
educational status. Logistic regression multivariate
models were used to evaluate the odds ratio (OR) for
success (versus relapse plus resistant) according to the
polymorphisms. Covariates used in the models were:
age, race/self-declared color (white), FTND score and
drug group. Studies have tested additive effects, includ-
ing some of the largest genetic studies on smoking be-
havior [23] and cessation [24]. However, the dominant
model was chosen based on previous studies: CHRNA2
rs2472553 (CC vs CT + TT) [13], CHRNA3 rs1051730
(CC vs CT + TT) [25], CHRNA5 rs16969968 (GG vs GA
+AA) [26], CHRNA5 rs2036527 (GG vs GA + AA) [27]
and CHRNB3 rs6474413 (GG vs GA +AA) [28]. Statis-
tical analyses were carried out using the SPSS software
(v.16.0), with the level of significance set at p ≤ 0.05.
Results
General, clinical, and genetic characteristics of patients
The clinical and demographic characteristics of the 1049
participants are shown in Table 1. Patients in the ana-
lysis had a mean age of 54.0 ± 15.0 years and 54.7% were
female. Race/color self-declared white was 65.8%. The
non-white was composed by patients self-declared as
blacks (7.2%) and intermediates (23.9%). In addition,
Asians (3.0%) and Amerindians (0.1%) were enrolled.
The minor allele frequencies and genotypic distributions
for the rs2472553, rs1051730, rs16969968, rs2036527
and rs6474413 were in accordance with Hardy–Wein-
berg equilibrium (Additional file 1 Table S2).
Success rate in smoking cessation according to
genotypes
Table 2 shows the success rate in smoking cessation for
patients according to the genotypes for CHRNA2
rs2472553, CHRNA3 rs1051730, CHRNA5 rs16969968
and rs2036527 and CHRNB3 rs6474413 polymorphisms.
The GA and AA genotypes for the CHRNA5 rs2036527
and rs16969968 polymorphisms were associated with
higher rates of success in smoking cessation treatment
in the female group (n = 389, n = 391); (P = 0.03, P = 0.01),
respectively. The frequencies of success according to
genotypes among the drug treatment groups were not
different. We found no association of CHRNA2
rs2472553, CHRNA3 rs1051730 and CHRNB3 rs6474413
polymorphisms with treatment outcome. The CHRNA2
rs2472553, CHRNA3 rs1051730 and CHRNB3 rs6474413
polymorphisms showed the following OR for success: 1.17
(95% CI = 0.81–1.69, p = 0.42); 1.02 (95% CI = 0.75–1.40,
p = 0.88); and 1.00 (95% CI = 0.57–1.75, p = 1.00),
respectively.
Table 3 shows a multivariate logistic regression ana-
lysis for the success in smoking cessation according to
the polymorphisms in CHRNA5 gene in women. The
GA or AA genotypes for CHRNA5 rs16969968 and
rs2036527 were associated with higher OR for success in
women (OR = 1.63; 95% CI = 1.04 to 2.54; P = 0.03) (OR
= 1.59; 95% CI = 1.02 to 2.48; P = 0.04), respectively.
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Multivariate models with the inclusion of variables were:
age, race/color, FTND score and drug group.
A stratified analysis by self-reported race showed the
following odds ratios for white women (OR = 1.67; 95%
CI = 1.06 to 2.43; P = 0.03 and OR = 1.64; 95% CI = 1.01
to 2.73; P = 0.04) and for non-white women (OR = 1.54;
95% CI = 1.03 to 3.23; P = 0.04 and OR = 2.06; 95% CI =
0.99 to 4.28; P = 0.05), respectively. Males and females
were analyzed together with the genotypes by sex inter-
action, but the finding was not significant.
Women showed a higher incidence of both depression
and anxiety than men (69.0% vs. 31.0%, P = 0.001; 63.8%
vs. 36.2%, P = 0.03, respectively). Given these differences,
the variables depression and/or anxiety were tested in
logistic regression. These variables were not associated
with treatment success in this model. However, GA and
AA genotypes for rs2036527 and rs16969968 polymor-
phisms remained significantly associated.
FTND score according to CHRNA2, CHRNA3, CHRNA5,
CHRNB3 polymorphisms
We did not observe significant differences in the FTND
score according to CHRNA2 rs2472553, CHRNA3
rs1051730, CHRNA5 rs16969968, CHRNA5 rs2036527
and CHRNB3 rs6474413 polymorphisms in the overall
patient group (n = 899) (Additional file 1: Table S3). In
addition, studied polymorphisms were not associated
with FTND score in multiple linear regression models
(Additional file 1: Table S4).
Discussion
The main findings of this study was the association of GA
and AA genotypes for both CHRNA5 rs16969968 and
rs2036527 polymorphisms with increased success rate in
smoking cessation treatment in women. Many studies
have identified the association of polymorphisms in the
CHRNA5-A3-B4 gene with smoking cessation in response
to smoking cessation therapies [2, 29–31]. Recently, our
group of researchers found the association of the
CHRNA4 rs10443196 and cytochrome P450 2B6
(CYP2B6) 785A >G polymorphisms with a higher success
rate in varenicline and bupropion treatment, respectively
[32, 33].
The association of the CHRNA5 rs16969968 poly-
morphism with higher rates of success in smoking cessa-
tion treatment in women is corroborated by previous
studies. As shown in vitro experiments Bierut et al. [14]
and Kuryatov et al. [34], individuals carrying the allele A
may express nAChR subtypes composed by α5 subunits
with reduced function. Bergen et al. [35] showed that a
lower frequency of the allele for rs1051730, which is in
strong linkage disequilibrium with rs16969968, was asso-
ciated with a higher withdrawal rate with NRT. Bergen
et al. pointed out that smokers with reduced function of
the α5 subunit and associated with increased ND may
have greater difficulty quitting. However, they suggested
that the prescription of NRT can improve cognitive per-
formance in smoking abstinence, maintaining the nor-
mal functioning of the brain after quitting, and this
effect may be stronger for individuals with the
rs1051730 risk allele. Similarly, Chen et al. [36] reported
that individuals with the AA genotype for the
rs16969968 had higher withdrawal rate in the treatment
with NRT. In the study by Jensen et al. [37], the A allele
was associated with lower rates of aversive effects to the
nicotine and also with improvement in cognitive control.
Jensen et al. suggested that the A allele may be import-
ant in tolerability and in response to treatments with
NRT. They added that, remarkably, the α5 subunit plays
an essential role in mediating aversive effects to the
Table 1 Clinical and demographic characteristics of patients undergoing smoking cessation (n = 1049)
Women (n = 574) Men (n = 475) P value
Age (years) 54 ± 18 54 ± 11 0.52
Race/color self-declared, White (%) 62.2 69.3 0.08
Body mass index (Kg/m2) 27 ± 6 27 ± 5 0.17
Educational status, college (%) 28.4 32.4 0.44
Hypertension (%) 45.1 53.7 0.006
Coronary artery disease (%) 14.1 26.9 < 0.001
Acute myocardial infarction (%) 14.5 31.2 < 0.001
Dyslipidemia (%) 40.6 46.1 0.07
Diabetes mellitus type 2 (%) 14.3 17.5 0.16
Depression (%) 24.7 13.7 < 0.001
Anxiety (%) 21.6 15.8 0.02
Obstructive pulmonar chronic disease (%) 16.9 15.4 0.50
Asthma (%) 1.6 1.1 0.47
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nicotine. Interestingly, King et al. [31] showed the asso-
ciation of others risk alleles for ND in locus chr15q25
with lower incidence of nausea. The authors suggest that
this may be explained by the tolerance, because individ-
uals with higher ND have higher daily intake of nicotine,
are more tolerant and therefore are less likely to experi-
ence nausea in response to a nicotinic partial agonist
such as varenicline. Therefore, reduced function of the
α5 subunit, the higher tolerability of NRT and vareni-
cline and improvement of cognitive control may be pos-
sible explanations for the association of rs16969968 with
success in this study. One other possibility is that the
rs16969968 can be in linkage disequilibrium with other
functional polymorphisms that could be involved in
smoking cessation process and/or mechanisms in re-
sponse to the NRT.
There was a higher frequency of depression and/or anx-
iety in the women’s group, which according to some studies
could reduce success rates in the smoking cessation treat-
ment [38–42]. Zawertailo et al. [38] conducted a study of
13,000 smokers and found that individuals with recurrent
depression were significantly less likely to quit smoking
compared to those with no history of depression. Goodwin
et al. [39] found that panic attacks and social anxiety dis-
order were more likely in female smokers than male
smokers. Stepankova et al. [40], in a study of 1730 smokers,
found that 289 had a history of depression. The tobacco ab-
stinence rate at 1 year was 32.5% for smokers with a history
of depression and 38.7% for those with no history. In our
study, although the frequencies of depression and anxiety
were higher in women than in men, these variables were
not associated with treatment outcome and rs16969968
and rs2036527 polymorphisms remained significantly asso-
ciated with smoking cessation in a multivariate model.
There are evidences that gender can be an important fac-
tor in smoking cessation process. Beltz et al. [43], evaluating
functional magnetic resonance imaging and behavioral data
from 50 adult daily smokers (23 women), found that
women had an increased nicotine tolerance when com-
pared to men. Smith et al. [44] found that women were
31% less likely to quit smoking than men. Pierce et al. [45]
reported significant sex differences in smoking cessation.
They observed the women had weight gain, higher preva-
lence of depression disorders and increased need of social
support to stop smoking.
Some studies showed that several factors may influ-
ence sex/gender differences [46], such as biopsychosocial
factors, menstrual cycle, hormonal [47, 48], having chil-
dren or not, and smoking cessation medication [44, 49].
In the present study, we found no association of
CHRNA2 rs2472553, CHRNA3 rs1051730 and CHRNB3
Table 2 Success rate in smoking cessation for patients
according to genotypes
CHRNA2 rs2472553
Patient groups Success rate (%)
CC CT TT P value
Overall group (n = 737) 44.7 47.5 46.2 0.81
Women (n = 395) 40.6 41.2 71.4 0.26
Men (n = 342) 49.4 54.5 16.7 0.19
CHRNA3 rs1051730
Patient groups Success rate (%)
CC CT TT P value
Overall group (n = 742) 44.8 45.6 50.6 0.64
Women (n = 396) 36.6 43.5 51.0 0.14
Men (n = 346) 54.3 47.9 50.0 0.52
CHRNA5 rs16969968
Patient groups Success rate (%)
GG GA AA P value
Overall group (n = 731) 43.0 46.6 54.3 0.18
Women (n = 389) 35.7 44.0 56.3 0.03
Men (n = 342) 52.0 49.1 51.5 0.87
CHRNA5 rs2036527
Patient groups Success rate (%)
GG GA AA P value
Overall group (n = 734) 43.9 44.4 55.0 0.13
Women (n = 391) 34.8 41.5 56.5 0.01
Men (n = 343) 53.8 47.5 52.6 0.53
CHRNB3 rs6474413
Patient groups Success rate (%)
GG GA AA P value
Overall group (n = 727) 46.0 46.0 45.9 1.00
Women (n = 388) 41.7 44.4 39.5 0.64
Men (n = 339) 51.9 47.8 52.8 0.67
Table 3 Multivariate logistic regression analysis for success in
smoking cessation according to the CHRNA5 rs16969968 (n =
389) and rs2036527 (n = 391) polymorphisms in women
OR 95% CI P value
Genotypes GA or AA for CHRNA5 rs16969968 1.63 1.04–2.54 0.03
Age 0.99 0.98–1.01 0.34
Race/color self-declared, White 1.20 0.76–1.91 0.43
FTND score 0.96 0.88–1.05 0.35
Drug group 1.01 0.83–1.25 0.86
OR 95% CI P value
Genotypes GA or AA for CHRNA5 rs2036527 1.59 1.02–2.48 0.04
Age 0.99 0.97–1.01 0.33
Race/color self-declared, White 1.28 0.82–2.00 0.29
FTND score 0.97 0.87–1.05 0.44
Drug group 1.01 0.83–1.24 0.93
FTND Fagerström test for nicotine dependence
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rs6474413 polymorphisms with treatment outcome. The
results of our study corroborate the findings of previous
studies. Ruyck et al. [50] and Sarginson et al. [2] found
no association for rs1051730 with outcome of treatment.
However, Munafo et al. [51] identified the T allele associ-
ated with decreased likelihood of smoking cessation.
Bergen et al. [35] associated the T allele with higher
withdrawal rates with NRT and lower withdrawal rate in
placebo treatment.
Regarding FTND score, several studies have identi-
fied the association of polymorphisms in genes encod-
ing nAChR alpha and beta subunits with FTND and,
number of cigarettes per day [52–57]. However, our
study found no significant association of the polymor-
phisms studied with FTND, consistent with the find-
ings of previous studies, which found no association
of CHRNA3 rs1051730, CHRNA5 rs16969968,
CHRNA5 rs2036527 or CHRNA5 rs6474413 polymor-
phisms with phenotypes related to smoking, including
ND [58–62].
Etter et al. [62] suggested that the reason for miss-
ing association of polymorphisms studied, including
rs16969968, can be explained by the difference in the
methods used, or due to the small sample size. Amos
et al. [61] did not find association of rs16969968
polymorphism with smoking behavior in either Afri-
can American case patients or African American con-
trol participants. The authors point out some
limitations of no association with the studied pheno-
types, as the sample size limited and also because in-
dividuals come from a single center; it is possible that
some degree of population structure influenced the
findings.
There are some limitations in our study that should be
mentioned. First, most patients treated at the PAF were
classified as moderately or highly dependent, which may
have affected the analysis of association between geno-
types and FTND score. Second, the race/color of patients
was self-report and we did not performed genetic ances-
try. Third, we did not perform the correction of P values
for multiple testing. Fourth, besides the available variables
used in the multivariate models other relevant factors that
could be important, such as the functionality of the recep-
tors, motivation to quit smoking, biopsychosocial and
others factors related to sex/gender, could have influenced
the results.
Conclusion
We showed that CHRNA5 rs16969968 and rs2036527
polymorphisms were associated with higher rates of
success in smoking cessation treatment in the female
group. These results might contribute to advances in
personalized medicine.
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